The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
New natural history of interferon‐β–treated relapsing multiple sclerosis
Abstract
Objective: To investigate the impact of interferon‐beta (IFNβ) on disease progression in relapsing‐remitting multiple sclerosis patients. Methods: A cohort of 1,504 relapsing‐remitting multiple sclerosis (1,103 IFNβ–treated and 401 untreated) patients was followed for up to 7 years. Cox proportional hazards regression adjusted for propensity score inverse weighting was used to assess the differences between the two groups for three different clinical end points: secondary progression (SP) and irreversible Expanded Disability Status Scale (EDSS) scores 4 and 6. Times from first visit and from date of birth were used as survival time variables. Results: The IFNβ–treated group showed a highly significant reduction in the incidence of SP (hazard ratio [HR], 0.38, 95% confidence interval [CI], 0.24–0.58 for time from 1st visit; HR, 0.36, 95% CI, 0.23–0.56 for time from date of birth; p < 0.0001), EDSS score of 4 (HR, 0.70, 95% CI, 0.53–0.94 for time from first visit; HR, 0.69, 95% CI, 0.52–0.93 for time from date of birth; p < 0.02), and EDSS score of 6 (HR, 0.60, 95% CI, 0.38–0.95 for time from first visit; HR, 0.54, 95% CI, 0.34–0.86 for time from date of birth; p ≤ 0.03) when compared with untreated patients. SP and EDSS scores of 4 and 6 were reached with significant delays estimated by times from first visit (3.8, 1.7, and 2.2 years) and from date of birth (8.7, 4.6, and 11.7 years) in favor of treated patients. Sensitivity analysis confirmed findings. Interpretation: IFN‐β slows progression in relapsing‐remitting multiple sclerosis patients. Ann Neurol 2007;61:300–306
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Lunceford, J. K., & Davidian, M. (2004) · Statistics in Medicine · doi:10.1002/sim.1903 · Cited by 1,674
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
Hirano, K., & Imbens, G. W. (2001) · Health Services and Outcomes Research Methodology · doi:10.1023/a:1020371312283 · Cited by 1,039
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 916
Assessing the sensitivity of regression results to unmeasured confounders in observational studies
Lin, D. Y., Psaty, B. M., & Kronmal, R. A. (1998) · Biometrics · doi:10.2307/2533848 · Cited by 742
PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, & the University of British Columbia MS/MRI Analysis Group (2001) · Neurology · doi:10.1212/wnl.56.12.1628 · Cited by 571
Early Statin Treatment Following Acute Myocardial Infarction and 1-Year Survival
Stenestrand, U. (2001) · JAMA · doi:10.1001/jama.285.4.430 · Cited by 530
Age at disability milestones in multiple sclerosis
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awh714 · Cited by 525
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Francis, G., Hughes, R. A., King, J. O., Mitchell, P. I., Joubert, J.-M., McLeod, J., Parker, G., Pollard, J. D., Sindic, C., Duprez, T. P. J., et al. (2001) · DIAL (Catholic University of Leuven) · doi:10.25405/ncl.34089345 · Cited by 472
Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Eight-year follow-up study of brain atrophy in patients with MS
Fisher, E., Rudick, R. A., Simon, J. H., Cutter, G., Baier, M., Lee, J. C., Miller, D., Weinstock-Guttman, B., Mass, M. K., Dougherty, D. S., et al. (2002) · Neurology · doi:10.1212/01.wnl.0000036271.49066.06 · Cited by 374
Rare Outcomes, Common Treatments: Analytic Strategies Using Propensity Scores
Braitman, L. E., & Rosenbaum, P. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00015 · Cited by 364
Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
Wee Yong, V., Chabot, S., Stuve, O., & Williams, G. (1998) · Neurology · doi:10.1212/wnl.51.3.682 · Cited by 344
Disability progression in multiple sclerosis is slower than previously reported
Tremlett, H., Paty, D., & Devonshire, V. (2006) · Neurology · doi:10.1212/01.wnl.0000194259.90286.fe · Cited by 343
EDMUS, a European database for multiple sclerosis.
Confavreux, C., Compston, D. A., Hommes, O. R., McDonald, W. I., & Thompson, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.8.671 · Cited by 313
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
Kappos, L., Traboulsee, A., Constantinescu, C., Erälinna, J. P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237994.95410.ce · Cited by 257
Gum, P. A., Thamilarasan, M., Watanabe, J., Blackstone, E. H., & Lauer, M. S. (2001) · JAMA · doi:10.1001/jama.286.10.1187 · Cited by 238
Age‐related disability in multiple sclerosis
Trojano, M., Liguori, M., Bosco Zimatore, G., Bugarini, R., Avolio, C., Paolicelli, D., Giuliani, F., De Robertis, F., Marrosu, M. G., & Livrea, P. (2002) · Annals of Neurology · doi:10.1002/ana.10147 · Cited by 186
Self-citationNormand, S.-L. T., Sykora, K., Li, P., Mamdani, M., Rochon, P. A., & Anderson, G. M. (2005) · BMJ · doi:10.1136/bmj.330.7498.1021 · Cited by 169
Change in MS-related disability in a population-based cohort: A 10-year follow-up study
Pittock, S. J., Mayr, W. T., McClelland, R. L., Jorgensen, N. W., Weigand, S. D., Noseworthy, J. H., Weinshenker, B. G., & Rodriguez, M. (2004) · Neurology · doi:10.1212/01.wnl.0000101724.93433.00 · Cited by 160
Estimating causal effects of public health education campaigns using propensity score methodology
Yanovitzky, I., Zanutto, E. L., & Hornik, R. (2005) · Evaluation and Program Planning · doi:10.1016/j.evalprogplan.2005.01.004 · Cited by 131
Vukusic, S., & Confavreux, C. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00426-4 · Cited by 126
Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a
Hardmeier, M., Wagenpfeil, S., Freitag, P., Fisher, E., Rudick, R. A., Kooijmans, M., Clanet, M., Radue, E. W., & Kappos, L. (2005) · Neurology · doi:10.1212/01.wnl.0000149516.30155.b8 · Cited by 104
Bermel, R. A., Puli, S. R., Rudick, R. A., Weinstock‐Guttman, B., Fisher, E., Munschauer, F. E., & Bakshi, R. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.1371 · Cited by 99
Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple Sclerosis
Biernacki, K., Antel, J. P., Blain, M., Narayanan, S., Arnold, D. L., & Prat, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.4.563 · Cited by 92
Placebo‐controlled clinical trials in multiple sclerosis: Ethical considerations
LUBLIN, F. D., & Reingold, S. C. (2001) · Annals of Neurology · doi:10.1002/ana.1025 · Cited by 71
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
Rudick, R. A., Cutter, G., Baier, M. L., Weinstock‐Guttman, B., Mass, M. K., Fisher, E., Miller, D. M., & Sandrock, A. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1203oa · Cited by 58
LUBLIN, F. D., & Reingold, S. C. (2001) · PubMed · Cited by 51
Observational Studies of Treatment Effectiveness: Some Cautions
Laupacis, A., & Mamdani, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-11-200406010-00014 · Cited by 45
Trojano, M., Russo, P., Fuiani, A., Paolicelli, D., Monte, E. D., Granieri, E., Rosati, G., Savettieri, G., Comi, G. P., Livrea, P., et al. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070620 · Cited by 28
Self-citationDatabases in MS research: pitfalls and promises
Weinshenker, B. G. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500402 · Cited by 26
Russo, P., Paolillo, A., Caprino, L., Bastianello, S., & Bramanti, P. (2004) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2003.00436.x · Cited by 5
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Levesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.b5087 · Cited by 1,182
Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Trojano, M., Lugaresi, A., et al. (2019) · JAMA · doi:10.1001/jama.2018.20588 · Cited by 546
Self-citationThe epidemiology of multiple sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 514
Metadata
- Authors
- Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., & Amato, M. P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2007-04
- Volume
- 61
- Issue
- 4
- Pages
- 300-306
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1982044564
- Cited by
- 270
- References
- 42
- FWCI
- 14.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.